Thanks for Playing: IG Reviews Medicare Discount Card Sponsors
This article was originally published in RPM Report
You may also be interested in...
CMS' Change of Heart: Niaspan will be Covered Under Medicare Part D
The federal government reverses position on Kos' HDL-elevating agent. The decision could have long-term consequences for the evolution of the cholesterol market.
The Perils of Part D
The Medicare drug benefit means more federal spending on pharmaceuticals-and more oversight of the industry. Two prominent prosecutors are experienced and ready. The first place they will look: contracting between manufacturers and plans and its influence on the formulary selection process.
Medicare Reaffirms Faith In Formulary Review Process Ahead Of Part D Changes
Dramatic transformation in the US Medicare Part D benefit design does not require any changes to CMS’ overall approach to reviewing formulary submissions from private drug plan sponsors, the agency says in its final guidance implementing the design changes for 2025.